Skip to main content

Table 4 Sample’s characteristics according to the presence of no DM, prediabetes and DM, accessed by fasting glucose

From: Diabetes mellitus in HIV-infected patients: fasting glucose, A1c, or oral glucose tolerance test – which method to choose for the diagnosis?

  Fasting glucose P value
<100 mg/dL 100–126 mg/dL ≥126 mg/dL
n (%) 169 (76.8) 44 (20) 7 (3.2)  
Sex [n (%)]     0.049
 Male 103 (60.9) 23 (52.3) 7 (100)  
 Female 66 (39.1) 21 (47.7) 0 (0)  
Age [years, [median (IR)] 43 (15) 51.5 (15) 45 (14) 0.027
Duration of HIV infection [years, [median (IR)] 8 (6) 8 (5.8) 8 (6) 0.782
cART [years, [median (IR)] 6 (7) 6 (5.8) 8 (6) 0.408
Clinical lipodystrophy [n (%)]     0.082
 Without CL 76 (45) 27 (61.4) 2 (28.6)  
 With CL 93 (55) 17 (38.6) 5 (71.4)  
Body Composition [n (%)]     0.004
 No lipodystrophy 26 (15.8) 4 (9.8) 1 (14.3)  
 Isolated central fat accumulation 46 (27.9) 22 (53.7) 1 (14.3)  
 Lipoatrophy 52 (31.5) 6 (14.6) 0 (0)  
 Mixed form of lipodystrophy 41 (24.8) 9 (22) 5 (71.4)  
BMI [(kg/m2), [median (IR)] 24.4 (5.8) 26.1 (5.5) 26 (3.4) 0.052
Waist circumference [cm, [median (IR)] 88 (16.5) 95 (13.5) 95 (15) 0.005
CD4 cell count [cells/mm3, [median (IR)] 486 (344) 525 (298) 605 (382) 0.643
HIV RNA (<50) [n (%)] 151 (100) 35 (100) 6 (100)  
Hepatitis C co-infection [n (%)] 56 (33.5) 6 (14.3) 2 (28.6) 0.034
CDC clinical categories [n (%)]     0.398
 A 89 (52.7) 27 (61.4) 3 (42.9)  
 B 3 (1.8) 2 (4.5) 0 (0)  
 C 77 (45.6) 15 (34.1) 4 (57.1)  
ART [n (%)]     
 IP 96 (56.8) 23 (52.3) 4 (57.1) 0.885
 NNRTI 79 (46.7) 20 (45.5) 3 (42.9) 0.999
 NRTI 163 (96.4) 41 (93.2) 6 (85.7) 0.157
HOMA-IR index [median (IR)] 1.5 (1.3) 3.2 (2.6) 9.3 (6,8) < 0.001
QUICKI index [median (IR)] 0.4 (0.1) 0.3 (0.04) 0.3 (0.04) < 0.001
Total cholesterol [mg/dL, median (IR)] 220 (66) 240.5 (86) 234 (79) 0.061
LDL- cholesterol [mg/dL, median (IR)] 127 (67) 149 (62) 146 (74) 0.136
HDL- cholesterol [mg/dL, median (IR)] 47 (18) 49 (22) 41 (22) 0.651
Triglycerides [mg/dL, median (IR)] 189.5 (197.8) 214.5 (207.8) 184 (88) 0.975
Statin use [n (%)] 35 (20.7) 8 (18.2) 3 (42.9) 0.312
Fibrate use [n (%)] 50 (29.6) 15 (34.1) 0 (0) 0.200
  1. DM diabetes mellitus, CL clinical lipodystrophy, cART combination antiretroviral therapy, BMI body mass index, ART antiretroviral therapy, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, HOMA homeostatic model assessment index, QUICKI quantitative insulin sensitivity check index, SD standard deviation, IR interquartile range
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us